XOMA Corporation (NASDAQ:XOMA) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a report released on Friday. The firm currently has a $33.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 8.41% from the stock’s previous close.

According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “

XOMA has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of XOMA Corporation in a research report on Thursday, August 10th. Wedbush upgraded XOMA Corporation from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $9.00 to $19.00 in a research report on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. XOMA Corporation currently has a consensus rating of “Buy” and a consensus target price of $30.00.

Shares of XOMA Corporation (NASDAQ:XOMA) opened at $30.44 on Friday. The company has a debt-to-equity ratio of 3.53, a current ratio of 3.45 and a quick ratio of 1.08. XOMA Corporation has a one year low of $3.96 and a one year high of $31.03.

TRADEMARK VIOLATION WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/12/xoma-corporation-xoma-rating-increased-to-strong-buy-at-zacks-investment-research.html.

A hedge fund recently bought a new stake in XOMA Corporation stock. EAM Investors LLC bought a new stake in XOMA Corporation (NASDAQ:XOMA) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 42,484 shares of the biotechnology company’s stock, valued at approximately $835,000. EAM Investors LLC owned 0.52% of XOMA Corporation at the end of the most recent quarter. Hedge funds and other institutional investors own 32.92% of the company’s stock.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.